Representative Matters
Repräsentative Angelegenheiten
代表事项
Public Offerings
- AquaVenture Holdings in its $117 million initial public offering
- Intellia Therapeutics in its $108 million initial public offering
- CRISPR Therapeutics in its $56 million initial public offering
Private Financings
- Moderna Therapeutics in its $110 million Series D financing and $500 million Series E financing
- Intellia Therapeutics in its $15 million Series A financing and $70 million Series B financing
- Nimbus Therapeutics in its $43 million Series B financing
- Scholar Rock in its $36 million Series B financing
Strategic Collaborations and M&A
- Teva Pharmaceuticals in its $3.2 billion acquisition of Auspex Pharmaceuticals
- Versant Ventures in its strategic transaction with Bayer to form BlueRock Therapeutics, with a combined financing amount of $225 million
- Foundation Medicine in its strategic collaboration with Roche, valued at more than $1 billion
- Quartet Medicine in its $595 million strategic collaboration with Merck
- Nimbus Therapeutics in its sale to Gilead, with $400 million upfront and the potential to receive an additional $800 million over time
- CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million upfront
- Padlock Therapeutics in its $225 million sale to Bristol Myers Squibb
- F-star Alpha in its agreement with Bristol-Myers Squibb
- Moderna Therapeutics in its collaboration with AstraZeneca to co-develop and co-commercialize immune-oncology mRNA Therapeutics.